Orchard Therapeutics Reports First Quarter 2021 Financial
TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for MLD on Track for Mid-2021 Following Type B RMAT Meeting with FDA Recent Publications, Including ADA-SCID Dataset in NEJM and Multiple Oral Presentations at ASGCT, Highlight Broad and Innovative Potential of HSC Gene Therapy Cash and Investments of Approximately $300M Provide Runway into First Half 2023 Following $150M Financing in February 2021 BOSTON and LONDON, May 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy lead...
Source: globenewswire.com